Aceto Corporation  

(Public, NASDAQ:ACET)   Watch this stock  
Find more results for ACET
11.56
+0.28 (2.48%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.03 - 11.59
52 week 7.90 - 11.59
Open 11.30
Vol / Avg. 224,938.00/114,020.00
Mkt cap 315.89M
P/E 16.76
Div/yield 0.05/1.90
EPS 0.69
Shares 27.33M
Beta 1.10
Inst. own 66%
May 10, 2013
Aceto Q3 2013 Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 3.96% 3.82%
Operating margin 5.80% 5.71%
EBITD margin - 7.64%
Return on average assets 5.88% 5.56%
Return on average equity 10.26% 10.33%
Employees 233 -
Carbon Disclosure Rating - -

Address

4 Tri Harbor Court
PORT WASHINGTON, NY 11050
United States - Map
+1-516-6276000 (Phone)
+1-516-6276093 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Aceto Corporation (Aceto) is primarily engaged in the sourcing, regulatory support, quality assurance, marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries. The Company operates in three segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. The Company has operations in nine countries; it distributes more than 1,100 chemical compounds used principally as finished products or raw materials. The Company has presence in China, Germany, France, the Netherlands, Singapore, India, Hong Kong, the United Kingdom and the United States, along with warehouses worldwide.

Officers and directors

Albert L. Eilender Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Salvatore J. Guccione President, Chief Executive Officer, Chief Operating Officer, Director
Age: 49
Bio & Compensation  - Reuters
Douglas A. Roth Chief Financial Officer, Senior Vice President
Age: 55
Bio & Compensation  - Reuters
Steven Rogers Senior Vice President, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Charles J. Alaimo Senior Vice President - Human Resources
Age: 46
Bio & Compensation  - Reuters
Raymond Bartone Senior Vice President - Nutritionals
Age: 50
Bio & Compensation  - Reuters
Frank DeBenedittis Senior Vice President - Corporate Business Development
Age: 58
Bio & Compensation  - Reuters
David B. Rosen Senior Vice President - Business Development
Age: 54
Bio & Compensation  - Reuters
Nicholas I. Shackley Senior Vice President - Pharmaceutical Ingredients
Age: 48
Bio & Compensation  - Reuters
Roger G. Weaving Jr. Senior Vice President - Performance Chemicals
Age: 53
Bio & Compensation  - Reuters